Benzinga

Benzinga

Benzinga

jueves, septiembre 03

Sangamo Therapeutics Inc

SGMOOTC
Trade with Public
Trade with Public
$0.1776
al cierre: May 14, 5:00 PM EST
$0.0777
-0.0999-56.25%
After hour: Jun 23, 9:29 AM EST
Panorámica generalNoticiasPrevisión de beneficiosEventosPrecios objetivoFinanzasSentimientoPropiedadComparar

Sangamo Therapeutics Inc Financials

Sangamo Therapeutics Inc (SGMO) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Sangamo Therapeutics Q1 EPS $(0.08) Misses $0.01 Estimate, Sales $1.442M Miss $33.725M Estimate

Sangamo Therapeutics (NASDAQ:SGMO) reported quarterly losses of $(0.08) per share which missed the analyst consensus estimate of $0.01 by 900 percent. This is a 42.86 percent increase over losses of $(0.14) per share
Benzinga Newsdesk

Earnings Scheduled For May 14, 2026

Benzinga Insights

PRO
Sangamo Therapeutics Q4 EPS $(0.11) Misses $(0.06) Estimate, Sales $14.200M Miss $16.475M Estimate

Sangamo Therapeutics (NASDAQ:SGMO) reported quarterly losses of $(0.11) per share which missed the analyst consensus estimate of $(0.06) by 83.33 percent. This is unchanged from the same period last year. The company
Benzinga Newsdesk

Earnings Scheduled For March 30, 2026

Benzinga Insights

PRO
Sangamo Therapeutics Q3 EPS $(0.11) Misses $(0.01) Estimate, Sales $581.000K Miss $34.400M Estimate

Sangamo Therapeutics (NASDAQ:SGMO) reported quarterly losses of $(0.11) per share which missed the analyst consensus estimate of $(0.01) by 1275 percent. This is a 375 percent decrease over earnings of $0.04 per share
Benzinga Newsdesk

Earnings Scheduled For November 6, 2025

Benzinga Insights

Datos y APIs: APIs de Benzinga · API de noticias de acciones · API de calificaciones de analistas · API de logotipos de empresas

Benzinga

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

© 2026 Benzinga | All Rights Reserved